Hipertin

Quick links to important sections

Hipertin

Treatment option:

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Hipertin

Property Description
Active ingredient Enalapril Maleate
Form Tablet (for oral use)
Pharmacological class Angiotensin-Converting Enzyme Inhibitor (ACE Inhibitor)
Common use Management of high blood pressure
Origin Synthetic Compound (Pro-drug)

What Type of Medicine is Hipertin (Enalapril Maleate)?

Hipertin is a prescription-only cardiovascular drug classified as an Angiotensin-Converting Enzyme Inhibitor, often referred to as an ACE Inhibitor. This synthetic compound is a single-ingredient product whose active substance, Enalapril Maleate, is formulated for oral administration in a tablet dosage form. The Enalapril chemical entity is recognized globally for its role in regulating blood pressure, with its application supported by extensive pharmacological research. This medicine is a standard tool used to help control elevated blood pressure, particularly in adults requiring sustained antihypertensive therapy.


Composition and Nature: Why is Enalapril a Pro-Drug?

The core component of the medicine is the active ingredient Enalapril, provided as the salt Enalapril Maleate, which is derived from a synthetic compound origin. Crucially, Enalapril is defined as a pro-drug, meaning it is biologically inactive upon ingestion and must undergo a metabolic process within the liver to be converted into the potent therapeutic compound, Enalaprilat. This necessary conversion is an intrinsic part of the drug's identity, distinguishing it from related ACE inhibitors that are fully active upon absorption. This design feature is a recognized aspect of the drug's therapeutic profile, intended to provide predictable effects.


What is the General Purpose of This Antihypertensive Agent?

The general purpose of this antihypertensive agent is to achieve sustained reduction of blood pressure by reducing peripheral vascular resistance. It does this by influencing the body’s fluid and blood pressure regulatory mechanism, the Renin-Angiotensin-Aldosterone System (RAAS). This systemic influence helps to reduce the overall force against which the heart works, consequently promoting efficient circulatory function, a benefit that is established in clinical practice. This medicine is typically recognized for its use in patients requiring daily, long-term management to help stabilize their circulatory health.

Regulatory References

  1. Enalapril: MedlinePlus Drug Information
  2. Enalapril - WHO Essential Medicines List (eEML)

What side effects are possible with Hipertin?

Possible Side Effects and Safety Information

The official safety profile for Hipertin (Enalapril Maleate) details adverse reactions across various physiological systems, classified by frequency based on clinical trial data, in accordance with regulatory standards (e.g., EMA/FDA).


Frequency-Classified Adverse Reactions

Classification Examples of Documented Adverse Reactions
Very Common (ge 1/10) Blurred vision, cough, dizziness.
Common (ge 1/100 to < 1/10) Headache, fatigue, nausea, diarrhea, hypotension (including orthostatic), syncope, and increases in serum creatinine or potassium (hyperkalaemia).
Rare (ge 1/10,000 to < 1/1,000) Hepatic failure, hepatitis, jaundice, agranulocytosis, and severe skin reactions like Stevens-Johnson syndrome.

Serious Adverse Reactions and Safety Constraints

Regulatory documents explicitly list several clinically significant and potentially life-threatening reactions. Angioedema—swelling of the face, tongue, glottis, and/or larynx—is a critical concern that may occur at any point during treatment. Excessive Symptomatic Hypotension may lead to complications such as acute renal failure, especially in vulnerable patients.

Use of Hipertin during the second and third trimesters of pregnancy is a contraindication due to the established risk of fetal toxicity, which can result in injury or death to the developing fetus. The medicine is also strictly restricted in individuals with a history of angioedema related to previous ACE inhibitor treatment or hereditary/idiopathic angioedema. Safety considerations are noted for specific groups, including patients with existing renal impairment and Black patients, who may experience a higher incidence of angioedema.

Overdose and Emergency Response

The official regulatory documentation for Hipertin (Enalapril Maleate) overdose describes specific clinical manifestations and mandates defined emergency responses. The primary documented presentation of an overdose is marked hypotension, which is a profound drop in blood pressure that can lead to related signs such as syncope (fainting), dizziness, and somnolence (drowsiness). Disturbances to the heart rhythm, including both tachycardia (accelerated rate) or bradycardia (slow rate), have also been noted in regulatory summaries.

Severe overdose scenarios carry the risk of progression to circulatory shock, acute renal failure, and hyperkalemia (dangerously high serum potassium levels), which are formally documented as life-threatening outcomes. Regulatory authorities mandate that any individual experiencing a suspected overdose must seek immediate medical attention and contact emergency services without delay.

Management is strictly symptomatic and supportive, as no specific antidote is known. The official procedural guidance includes placing the patient in a supine position and initiating volume expansion with intravenous saline solution to rapidly treat severe hypotension. For severe cases, the active metabolite, Enalaprilat, is documented as dialyzable for removal. Continuous hospital monitoring of blood pressure, serum electrolytes, and renal function is required until the patient's condition stabilizes.

Therapeutic Uses of Hipertin

What Hipertin Treats: Main Uses and Benefits

The medication is applied across therapeutic domains involving cardiovascular functional stress. Specifically, it is commonly used to help with three main clinical scenarios, which address symptoms related to systemic imbalance and underlying cardiac weakness.

Hipertin is used for managing chronically elevated systemic blood pressure (Essential Hypertension), supporting the clinical course of Symptomatic Heart Failure, and serving as a preventative therapy for Asymptomatic Left Ventricular Dysfunction. The primary goal is to address symptom clusters that may become intense or disruptive.

“The treatment primarily focuses on providing supportive relief that assists with maintaining functional stability for patients facing chronic cardiovascular conditions.”

In patients with heart failure, the medication helps manage symptom clusters like fluid retention and exertional shortness of breath, promoting improved comfort during daily activities. For high blood pressure, this daily management contributes to easing the continuous workload on the heart and arteries, offering supportive benefit that helps reduce the risk of major cardiovascular events.

Quick Fact: Relief for Circulatory Overload Symptoms

Eligibility and Restrictions for Use

The eligibility for Hipertin, containing the ACE inhibitor Enalapril Maleate, is strictly defined by regulatory documents, distinguishing between approved use, restricted use, and absolute prohibition (contraindication).

Populations Excluded from Use (Contraindications)

Hipertin must not be used by patients who have a known hypersensitivity to enalapril or any other ACE inhibitor, or a history of swelling (angioedema) related to previous ACE inhibitor treatment. It is also contraindicated during the second and third trimesters of pregnancy due to risks of fetal injury. Co-administration is prohibited with aliskiren in patients with diabetes or moderate-to-severe kidney impairment, and it cannot be used within 36 hours of taking sacubitril/valsartan.

Age and Condition-Based Eligibility

Category Eligibility Status (Regulatory Wording)
Age Groups Approved for adults and children older than one month for hypertension. Not recommended for neonates (infants le 1 month).
Kidney Function Use is not recommended in pediatric patients with severe renal impairment (GFR < 30 mL/min/1.73 m^2). Caution is required for all patients with impaired renal function.
Outflow Obstruction Use with caution in patients with conditions like aortic or mitral valve stenosis or hypertrophic cardiomyopathy.
Lactation Not recommended as the drug is secreted into breast milk.

These official rules determine who is eligible to begin or continue treatment with Hipertin.

What should I know about interactions with other medicines?

Official Interaction Restrictions and Classifications

Hipertin (Enalapril Maleate) has documented interactions with other medicines and products, which are structured by formal regulatory classifications, including contraindications and significant use restrictions.

Classification Interacting Agents Regulatory Constraint
Contraindicated Combination Sacubitril/Valsartan (ARNI) A mandatory 36-hour wash-out period is required when switching to or from Enalapril due to the risk of angioedema.
Conditional Contraindication Aliskiren (Renin Inhibitor) Prohibited in patients with diabetes or renal impairment (GFR lt 60 mL/min) due to the risk of hypotension and hyperkalemia.
Exposure Modification Lithium Co-administration leads to increased serum lithium concentrations and potential toxicity due to reduced renal clearance of lithium.
Hyperkalemia Risk (Additive) Potassium-Sparing Diuretics (e.g., Spironolactone), Potassium Supplements, Potassium-Containing Salt Substitutes Co-use is not generally recommended because of an additive pharmacodynamic effect on potassium retention.
Pharmacodynamic Effects NSAIDs (Non-Steroidal Anti-Inflammatory Drugs) May cause deterioration of renal function, particularly in the elderly or volume-depleted, and may reduce the antihypertensive effect.

Food: The regulatory label documents no clinically significant effect on absorption of Enalapril Maleate when taken with food.

Mechanism of Action

The mechanism-of-action of Hipertin involves modulation of transmembrane calcium flux in specific cell types. Hipertin functions as a L-type calcium channel antagonist, binding to the alpha1 subunit of the voltage-dependent calcium channel (VDCC) primarily found on vascular smooth muscle cells (VSMCs). This interaction leads to the inhibition of calcium ion ( Ca^2+) entry into the cytoplasm of the VSMCs. The consequent reduction in intracellular Ca^2+ concentration limits the phosphorylation of the myosin light chain, thereby diminishing the interaction between actin and myosin filaments. This intracellular cascade results in a decrease in the inherent contractile tone of the vascular smooth muscle surrounding the arterial walls. The resulting systemic physiological consequence is a reduction in peripheral vascular resistance through the mechanism of vasodilation, which modulates the forces exerted on the circulatory system. Hipertin exhibits greater selectivity for vascular tissue over cardiac tissue channels.

Dosage and Administration Information

Official Administration and Use

Hipertin, the oral tablet formulation of enalapril maleate, is intended exclusively for oral administration and must be swallowed with liquid. The medicine can be taken with or without food, as its absorption is not influenced by meals. For a missed dose, the standard protocol is to skip the missed dose and resume the normal schedule; taking a double dose is not permitted. The drug is a pro-drug, and its active effect on the body is typically delayed, beginning approximately three to four hours after intake.


Standard Labeled Dosing Regimens

The dose and frequency are specifically determined by the condition being addressed.

Indication Typical Starting Dose Maximum Daily Dose Frequency
Hypertension 5 mg once daily 40 mg Once daily
Heart Failure 2.5 mg twice daily (BID) 40 mg Twice daily

Titration and Adjustment Rules

Administration requires specific adjustments for certain patient groups. For example, individuals with impaired kidney function are prescribed a lower starting dose (e.g., 2.5 mg daily for severe renal impairment). Initial treatment for conditions like heart failure requires gradual dose increases (titration) over a period of 2 to 4 weeks, with the process requiring close observation. A dose reduction to 2.5 mg once daily is also applied when the medicine is co-administered with diuretics.

Recent Clinical Evidence

Research evidence / Overview of studies for Hipertin

Evidence for use in Managing High Blood Pressure (Essential Hypertension)

Research examining the use of this medicine for high blood pressure was evaluated in studies ranging from short-term and intermediate-term Randomized Controlled Trials (RCTs). These studies primarily monitored outcomes related to systemic or functional imbalance, such as changes in supine and standing systolic and diastolic blood pressure across different time points. The trials also explored the effects in populations with varying grades of high blood pressure, including initial research examining a small number of children.

The studies described patterns of reduced systolic and diastolic blood pressure measurements across various severity grades of hypertension in the observed populations. Studies observed that the magnitude of the change in blood pressure varied between certain ethnic groups.


Evidence for use in Treating Symptomatic Heart Failure

The evidence for use in conditions marked by functional limitations has been primarily derived from large-scale, long-term, placebo-controlled trials. These studies was studied for outcomes related to systemic or functional imbalance, including the frequency of hospitalization for heart failure and all-cause mortality. Studies also monitored outcomes reflecting daily functioning or activity level and patient-reported outcomes describing perceived discomfort.

Studies described observations regarding mortality rates and the frequency of heart failure-related hospitalizations in the observed populations. Research also reports changes measured during the study period related to functional capacity. Subgroup findings are uncertain regarding the effects of varying doses, where one comparative study monitored outcomes in patient groups receiving different dosages.


Evidence for use in Preventing Progression of Asymptomatic Left Ventricular Dysfunction

Research examined the use of this medicine in a unique population of adults who had left ventricular dysfunction but had not yet developed clinical signs of heart failure. These prevention trials used a long-term, randomized design, and the research explored endpoints such as the rate of progression to overt symptomatic heart failure and the incidence of related hospitalization. Long-term trials described observations regarding the progression to symptomatic heart failure and the incidence of heart failure hospitalization in the observed populations.


What the Research Landscape Shows Regarding Uncertainty and Gaps

While a significant body of research exists, there are still areas where certainty remains low and the evidence base is incomplete. Comparative evidence is limited when attempting to evaluate this medicine against all other treatment options for heart failure and high blood pressure. Research limitation frames suggest that data for certain groups, particularly infants and very young children in both hypertension and asymptomatic ventricular dysfunction, remain insufficient. Long-term outcomes are not fully characterized for the asymptomatic population.

Key Studies & References

  1. WHO Model List of Essential Medicines (Enalapril Maleate Inclusion)

Frequently Asked Questions (FAQ)

Common questions about Hipertin (FAQ)

Q: Is there a generic version of Hipertin available?

A: Yes. The active component of Hipertin, which is Enalapril Maleate, has been approved by the FDA and other global regulatory agencies as a generic formulation. This means that generic versions containing the same active ingredient are available.

Q: Is Hipertin used for anything other than its main approved use?

A: According to official regulatory documents, this medicine is indicated for three specific conditions: the management of High Blood Pressure (Hypertension), the treatment of symptomatic Congestive Heart Failure, and the prevention of progression in Asymptomatic Left Ventricular Dysfunction.

Q: What is the typical age range of people who are prescribed Hipertin?

A: Official documentation indicates that the medicine is approved for use in adults and in children older than one month for the treatment of hypertension. It is not recommended for use in infants younger than one month of age.

Q: Does Hipertin require any special monitoring or blood tests?

A: Yes. Official information indicates that monitoring may be necessary during treatment. Due to the medicine's effect on the kidneys and potassium levels, the monitoring of kidney function markers ( serum creatinine) and potassium ( hyperkalemia) levels has been noted in the official guidance.

Q: Does Hipertin have a black box warning from the FDA or similar bodies?

A: Yes. The medicine carries a required FDA Boxed Warning (a specific type of safety alert) regarding Fetal Toxicity. The warning advises that discontinuation of the drug should occur as soon as possible if pregnancy is detected.

Q: Does Hipertin affect mood or cause emotional changes?

A: Yes. According to regulatory data, the medicine can affect mood and emotion. Documented psychiatric side effects include Depression (listed as Common) and Confusion (listed as Uncommon).

Q: Can Hipertin affect my ability to drive or operate machinery?

A: Yes. Due to documented side effects like dizziness and fatigue, the medicine may affect a patient’s alertness and coordination. Official information notes that patients should be aware of their individual reaction to the medicine before engaging in tasks such as driving or operating machinery.

Q: Does Hipertin affect blood sugar levels?

A: Yes. EMA regulatory data indicates that the medicine may affect blood sugar levels. Specifically, Hypoglycemia (low blood sugar) is listed as an Uncommon adverse reaction.

Q: Why do some patients experience a metallic taste with Hipertin?

A: Changes in taste perception are listed as a Common adverse reaction in regulatory safety profiles. This change is generally described as a taste alteration, which is known to include experiences such as a metallic taste.

Q: Is Hipertin considered a strong medication?

A: Hipertin is classified as an Angiotensin-Converting Enzyme ( ACE) Inhibitor. This class of medicine is known to influence the Renin-Angiotensin-Aldosterone System, which is a key mechanism the body uses to regulate blood pressure and vascular resistance.

Q: Is it better to take Hipertin in the morning or at night?

A: The regulatory label describes the medicine as administered once or twice daily, with or without food. The product information does not contain a specific instruction indicating whether taking it in the morning or at night is definitively better.

Q: Can Hipertin be taken with other prescription medications for [main condition]?

A: Regulatory guidance specifies certain drug combinations that are strictly prohibited, such as use with Sacubitril/Valsartan, and other agents that require close monitoring. The official product information describes the necessity of reviewing all prescription medication combinations with a health professional due to potential interactions.

Q: Is Hipertin safe for older adults or seniors?

A: Official documents note that older adults may process medications more slowly. Because of potential age-related changes in kidney function, dose adjustments or a modified dosing schedule may be considered by a prescriber.

Q: Are there restrictions on using Hipertin if I have liver problems?

A: The official product information warns about the rare but serious possibility of developing liver issues, including hepatic failure, while taking the medication. For patients with pre-existing liver impairment, regulatory guidance indicates that close monitoring is described as a consideration during treatment.

Q: Does Hipertin interact with herbal supplements or vitamins?

A: Regulatory materials describe the importance of a patient informing their healthcare provider about all vitamins and herbal supplements being taken. This is because safety information regarding the co-administration of these products with Hipertin is often incomplete or not fully tested.

Q: Does drinking coffee or caffeine impact how Hipertin works?

A: Regulatory interaction information indicates that caffeine may have additive effects with other blood pressure-lowering agents. Official information notes that caution has been advised due to caffeine's ability to impact blood pressure and heart rate.

Q: How long do the side effects of Hipertin typically last?

A: While the full duration of all adverse reactions is not precisely documented, common effects like dizziness or weakness may improve within a few days or weeks of starting treatment. The cough sometimes associated with ACE inhibitors can take longer to resolve after the medicine is stopped.

Q: Can Hipertin cause weight gain or weight loss?

A: Significant weight gain or weight loss is not listed as a common or very common side effect in the regulatory safety profile. However, official information notes that substantial weight changes can sometimes be a symptom of a serious complication, such as issues with kidney function.

Q: What happens if a patient suddenly stops taking Hipertin?

A: Abruptly stopping this medicine has not been linked to a sudden, immediate increase in blood pressure, according to some data. However, for most drugs used to lower blood pressure, the general practice described for most antihypertensive drugs is a gradual discontinuation under medical guidance.

How should Hipertin be stored and disposed of?

How to Store and Dispose of Hipertin (Enalapril Maleate)

The storage and disposal of Hipertin tablets must adhere to official regulatory requirements to ensure product integrity and safety.


Storage Conditions

Requirement Official Regulatory Statement
Temperature Store not above 25°C (77°F) (Controlled Room Temperature).
Container Must be kept in the original container and kept tightly closed.
Protection Store to protect the tablets from moisture and keep out of the sight and reach of children.

Disposal Instructions

Expired or unused Hipertin must be discarded safely. Disposal should follow the guidance of local regulations, often utilizing a drug take-back program or event. The medicine should not be disposed of in wastewater or flushed down a toilet unless specifically instructed by the product labeling.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Equivalent of Hipertin found in:

A-Z Index: